Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia

Leukemia. 2016 Nov;30(11):2232-2234. doi: 10.1038/leu.2016.157. Epub 2016 May 25.

Authors

S Schliffke¹, N Akyüz¹, C T Ford¹, T Mährle¹, T Thenhausen², A Krohn-Grimberghe², S Knop³, C Bokemeyer¹, M Binder¹

Affiliations

¹ Department of Oncology and Hematology, BMT with Section Pneumology, Hubertus Wald Tumorzentrum/UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² LYTIQ GmbH, Paderborn, Germany.
³ Department of Medicine II, Hematology and Oncology, University Hospital of Würzburg, Würzburg, Germany.

PMID: 27220665
DOI: 10.1038/leu.2016.157

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Aged
Autoimmune Diseases / complications
Autoimmune Diseases / immunology*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / immunology
Male
Middle Aged
Piperidines
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Remission Induction
T-Lymphocytes / immunology*

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine